SARS (Severe Acute Respiratory Syndrome) Clinical Trial
Official title:
Effectiveness of Quercetin In The Treatment of SARS-COV 2
In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins. Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.
Properties - Anti-oxidant, vascular protector - Inhibition of platelet aggregation, vasorelaxant , arterial relaxant - Anti-hypertensive , especially by certain derivatives (quercetin-3-glucuronic acid) - Nephroprotective in rats, protects against the nephrotoxicity of gentamicin - Anticancer , with immunostimulatory activity and inducer of apoptosis, with activity on the shock proteins HSP (heat shock proteins) hsp27 and hsp70 - Antitumor activity against prostate cancer and certain breast cancer cells - Prevention of cardiac toxicity from doxorubicin, with resveratrol - Protection against gastric inflammation associated with Helicobacter pylori infection by activity on MAPK, BCL-2, BAX. - Increases the antitoxic activity of the liver - Pancreatic lipase inhibitor, potential action in weight gain - Anti-inflammatory - Anti-allergic, inhibition of mast cell degranulation, with a preventive effect, reduction of inflammation linked to eosinophils (such as isoquercitrin regulates the Th1 / Th2 balance - Antiviral (dose-dependent reduction of infectivity, decreases intracellular replication) - Inhibition of rhinovirus replication - Influenza prophylaxis by quercetin or its derivatives (quercetin-3-O-α-L-rhamnopyranoside), opposes the pro-oxidant effects induced by the influenza virus, antioxidant therapy could be used to prevent serious complications associated with influenza - In vitro inhibition of the penetration of the Ebola virus by quercetin-3-O-glucoside - Antiviral activity against Zika virus, hepatitis B virus, hepatitis C, Epstein-Barr virus EBV and antitumor against human gastric carcinoma ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04615052 -
Home-based Exercise in COVID-19 Survivors
|
N/A | |
| Completed |
NCT04720794 -
A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
|
N/A | |
| Enrolling by invitation |
NCT04659486 -
Adolescents With COVID-19/MIS-C at HCFMUSP
|
N/A | |
| Completed |
NCT04784481 -
Ivermectin Reproposing for Mild Stage COVID-19 Outpatients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04584658 -
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
|
||
| Active, not recruiting |
NCT04558476 -
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation
|
Phase 2 | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
| Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
| Completed |
NCT04701710 -
Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05054075 -
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
|
Phase 2 | |
| Withdrawn |
NCT04590274 -
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
|
Phase 1 | |
| Completed |
NCT04644159 -
Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]
|
||
| Recruiting |
NCT04978025 -
Colloidal Silver, Treatment of COVID-19
|
N/A | |
| Enrolling by invitation |
NCT04540185 -
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
|
Phase 3 | |
| Recruiting |
NCT04497454 -
Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19)
|
N/A | |
| Active, not recruiting |
NCT04382391 -
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
|
N/A | |
| Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT04390412 -
Low Dose Radiotherapy in COVID-19 Pneumonia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04560257 -
High Flow Nasal Cannula HFNC In Covid-19 Patients
|
N/A |